Nous sommes auteurs et co-auteurs de nombreuses publications dans des revues médicales et scientifiques à comité de lecture, consultables en ligne sur notre site.
080
Prevalence of gout in the adult population of France.
Bardin T1,2,3, Bouée S4, Clerson P5, Chalès G6, Flipo RM7, Lioté F1,2,3, Perez V8, Poiraud T8, Schaeverbeke T9, Richette P1,2,3.
Author information
• 1 Assistance Publique Hôpitaux de Paris, Hôpital Lariboisière, Rheumatology department, F-75010, Paris, France.
• 2 University Paris Diderot, Sorbonne Paris Cité, F-75205, Paris, France.
• 3 Inserm, UMR 1132, F-75010, Paris, France.
• 4 Cemka, Statistic, Bourg La Reine, France.
• 5 Orgamétrie Biostatistiques, Roubaix, France.
• 6 CHU Rennes, Hôpital Sud, Rheumatology department, and University of Rennes 1, France.
• 7 Rheumatology department, University Hospital of Lille, and University of Lille 2, 59000, Lille, France.
• 8 Ménarini France, 94633, Rungis, France.
• 9 Rheumatology department, Hôpital Pellegrin 33076, and University Bordeaux Segalen, France.
Abstract
OBJECTIVE:
To estimate adult gout prevalence in France.
METHODS:
We used a previously established phone questionnaire that allowed for classifying patients as gouty or non-gouty by 2 logistic regression models and 1 Classification and Regression Tree (CART) method, the sensitivity and specificity of which were all more than 80%. The full questionnaire was administered by phone to subjects who acknowledged present or past non-traumatic acute pain in a peripheral joint, the others being classified as non-gouty. A random sample of adults residing in France was derived from the national telephone (home and mobile) directory by the quota method and further redressed to match the French population. The target size for the interview survey conducted in March and June 2013 was 10,000 participants.
RESULTS:
We interviewed 10,026 participants. All three models (2 logistic regression and CART models) converged to an estimated gout prevalence of 0.9%. This was lower than that estimated by self-reporting only (3.7%; 95% CI: 3.3-4.1). The prevalence was higher for males than females and increased with age but did not differ by area of France.
CONCLUSION:
Gout prevalence in the adult population of France in 2013 was estimated at 0.9%. Studies using self-reporting only might overestimate the prevalence.
079
Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
Hachulla E1, Hatron PY1, Carpentier P2, Agard C3, Chatelus E4, Jego P5, Mouthon L6, Queyrel V7, Fauchais AL8, Michon-Pasturel U9, Jaussaud R10, Mathian A11, Granel B12, Diot E13, Farge-Bancel D14, Mekinian A15, Avouac J16, Desmurs-Clavel H17, Clerson P18; SEDUCE study group.
078
Evaluation of patients' expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index - the benefica study.
Demoly, Aubier, de Blay, Wessel, Clerson, Maigret.
077
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population.
Hachulla E1, Clerson P2, Airò P2, Cuomo G2, Allanore Y2, Caramaschi P2, Rosato E2, Carreira PE2, Riccieri V2, Sarraco M2, Denton CP2, Riemekasten G3, Pozzi MR2, Zeni S2, Mihai CM2, Ullman S2, Distler O2, Rednic S2, Smith V2, Walker UA2, Matucci-Cerinic M2, Müller-Ladner U2, Launay D1; on behalf of the EUSTAR co-workers.
076
Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).
Gilet H1, Arnould B1, Fofana F1, Clerson P2, Colombel JF3, D'Hondt O2, Faure P4, Hagège H5, Nachury M6, Nahon S7, Tucat G8, Vandromme L9, Cazala-Telinge I10, Thibout E10.
075
Validation of the Test Your Memory (F-TYM Test) in a French Memory Clinic Population.
Postel-Vinay N1, Hanon O, Clerson P, Brown JM, Ménard J, Paillaud E, Alonso E, Pasquier F, Pariel S, Belliard S, Péré JJ, Belmin J.
074
Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis.
Mouthon L1, Carpentier PH1, Lok C1, Clerson P1, Gressin V1, Hachulla E1, Bérezné A1, Diot E1, Khau Van Kien A1, Jego P1, Agard C1, Duval-Modeste AB1, Sparsa A1, Puzenat E1, Richard MA1; on behalf of the ECLIPSE Study Investigators.
073
EVAPIL-R Scale: Continuous Development and Validation of a Tool to Assess Patient-Reported Tolerability of Different Contraceptive Methods in Longitudinal Studies.
Clerson P, Graesslin O, Gater A, Taylor F, Filonenko A, Schellschmidt I, Rosen K.
072
Identification of patients with gout: elaboration of a questionnaire for epidemiological studies.
Richette P, Clerson P, Bouée S, Chalès G, Doherty M, Flipo RM, Lambert C, Lioté F, Poiraud T, Schaeverbeke T, Bardin T.
071
Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
Agard C, Carpentier P, Mouthon L, Clerson P, Gressin V, Bérezné A, Diot E, Jego P, Lok C, Sparsa A, Chatelus E, Kien AK, Quéré I, Sibilia J, Hachulla E.